TY - JOUR
T1 - Connexins in neuromyelitis optica
T2 - A link between astrocytopathy and demyelination
AU - Richard, Chloé
AU - Ruiz, Anne
AU - Cavagna, Sylvie
AU - Bigotte, Maxime
AU - Vukusic, Sandra
AU - Masaki, Katsuhisa
AU - Suenaga, Toshihiko
AU - Kira, Jun Ichi
AU - Giraudon, Pascale
AU - Marignier, Romain
N1 - Funding Information:
We thank Nathalie Dufay from NeuroBioTec-Banques (Hospices Civils de Lyon, France) for providing Neuromyelitis Optica patients' samples and plasmaphereses, Sandrine Parrot from NeuroDialytTics plateform (Centre for Research in Neurosciences of Lyon, France) for performing extracellular glutamate dosage and Elisabeth Errazuriz and Christel Cassin from CIQLE (Centre d'Imagerie Quantitative Lyon-Est, France) for their expertise in electron microscopy. The present study is supported by a grant from ARSEP foundation; a grant provided by the French State and handled by the “Agence Nationale de la Recherche” within the framework of the “Investments for the Future” program, under the reference ANR-10-COHO-002 Observatoire Français de la Sclérose en Plaques (OFSEP) and by a grant from “Déchaine ton Coeur” association.
Publisher Copyright:
© The Author(s) (2020).
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Neuromyelitis optica, a rare neuroinflammatory demyelinating disease of the CNS, is characterized by the presence of specific pathogenic autoantibodies directed against the astrocytic water channel aquaporin 4 (AQP4) and is now considered as an astrocytopathy associated either with complement-dependent astrocyte death or with astrocyte dysfunction. However, the link between astrocyte dysfunction and demyelination remains unclear. We propose glial intercellular communication, supported by connexin hemichannels and gap junctions, to be involved in demyelination process in neuromyelitis optica. Using mature myelinated cultures, we demonstrate that a treatment of 1 h to 48 h with immunoglobulins purified from patients with neuromyelitis optica (NMO-IgG) is responsible for a complement independent demyelination, compared to healthy donors' immunoglobulins (P 5 0.001). In parallel, patients' immunoglobulins induce an alteration of connexin expression characterized by a rapid loss of astrocytic connexins at the membrane followed by an increased size of gap junction plaques (+ 60%; P 5 0.01). This was co-observed with connexin dysfunction with gap junction disruption (-57%; P 5 0.001) and increased hemichannel opening (+ 17%; P 5 0.001), associated with glutamate release. Blocking connexin 43 hemichannels with a specific peptide was able to prevent demyelination in co-treatment with patients compared to healthy donors' immunoglobulins. By contrast, the blockade of connexin 43 gap junctions with another peptide was detrimental for myelin (myelin density -48%; P 5 0.001). Overall, our results suggest that dysregulation of connexins would play a pathogenetic role in neuromyelitis optica. The further identification of mechanisms leading to connexin dysfunction and soluble factors implicated, would provide interesting therapeutic strategies for demyelinating disorders.
AB - Neuromyelitis optica, a rare neuroinflammatory demyelinating disease of the CNS, is characterized by the presence of specific pathogenic autoantibodies directed against the astrocytic water channel aquaporin 4 (AQP4) and is now considered as an astrocytopathy associated either with complement-dependent astrocyte death or with astrocyte dysfunction. However, the link between astrocyte dysfunction and demyelination remains unclear. We propose glial intercellular communication, supported by connexin hemichannels and gap junctions, to be involved in demyelination process in neuromyelitis optica. Using mature myelinated cultures, we demonstrate that a treatment of 1 h to 48 h with immunoglobulins purified from patients with neuromyelitis optica (NMO-IgG) is responsible for a complement independent demyelination, compared to healthy donors' immunoglobulins (P 5 0.001). In parallel, patients' immunoglobulins induce an alteration of connexin expression characterized by a rapid loss of astrocytic connexins at the membrane followed by an increased size of gap junction plaques (+ 60%; P 5 0.01). This was co-observed with connexin dysfunction with gap junction disruption (-57%; P 5 0.001) and increased hemichannel opening (+ 17%; P 5 0.001), associated with glutamate release. Blocking connexin 43 hemichannels with a specific peptide was able to prevent demyelination in co-treatment with patients compared to healthy donors' immunoglobulins. By contrast, the blockade of connexin 43 gap junctions with another peptide was detrimental for myelin (myelin density -48%; P 5 0.001). Overall, our results suggest that dysregulation of connexins would play a pathogenetic role in neuromyelitis optica. The further identification of mechanisms leading to connexin dysfunction and soluble factors implicated, would provide interesting therapeutic strategies for demyelinating disorders.
UR - http://www.scopus.com/inward/record.url?scp=85091323933&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091323933&partnerID=8YFLogxK
U2 - 10.1093/brain/awaa227
DO - 10.1093/brain/awaa227
M3 - Article
C2 - 32889550
AN - SCOPUS:85091323933
SN - 0006-8950
VL - 143
SP - 2721
EP - 2732
JO - Brain
JF - Brain
IS - 9
ER -